SEC Company Response from Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259) (OTLC) — Jun 25, 2018
Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)
Date: June 25, 2018 · CIK: 0000908259 · Accession: 0001193125-18-201642
AI Filing Summary & Sentiment
Letter
Mateon Therapeutics, Inc.
701 Gateway Blvd., Suite 210
South San Francisco, California 94080
June 25, 2018
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 3561
Washington, D.C. 20549
Re: Mateon Therapeutics, Inc.
Registration Statement on Form S-1
Filed on June 13, 2018
File No. 333- 225600
Acceleration Request
Ladies and Gentleman:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Mateon Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-1 be accelerated to Tuesday, June 26, 2018, at 5:00 p.m. EST, or as soon as thereafter practicable.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Any questions should be addressed to Megan N. Gates, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111, telephone (617) 348-4443.
Very truly yours,
Mateon Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Mateon Therapeutics, Inc. 701 Gateway Blvd., Suite 210 South San Francisco, California 94080 June 25, 2018 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Re: Mateon Therapeutics, Inc. Registration Statement on Form S-1 Filed on June 13, 2018 File No. 333- 225600 Acceleration Request Ladies and Gentleman: Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Mateon Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-1 be accelerated to Tuesday, June 26, 2018, at 5:00 p.m. EST, or as soon as thereafter practicable. The cooperation of the staff in meeting the timetable described above is very much appreciated. Any questions should be addressed to Megan N. Gates, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111, telephone (617) 348-4443. Very truly yours, Mateon Therapeutics, Inc. /s/ Matthew M. Loar Matthew M. Loar Chief Financial Officer cc: Securities and Exchange Commission Jeffrey Gabor Mateon Therapeutics, Inc. William D. Schwieterman, M.D., Chief Executive Officer Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Megan N. Gates, Esq. Melanie Ruthrauff Levy, Esq. Jenna M. Stewart, Esq.